A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy.
暂无分享,去创建一个
S. Mackinnon | H. Waldmann | D. Linch | R. Chopra | P. Mahendra | R. Pettengell | A. Goldstone | D. Milligan | R. Chakraverty | S. Devereux | G. Hale | S. Chakrabarti | S. Robinson | J. Marsh | P. Kottaridis | S. Schey | P. Kottaridis | C. Williams | G. Morgan | Panos Kottaridis | Prem Mahendra | S Schey